Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib and SBRT in EGFR-mutant Non-squamous NSCLC
NCT03153358Phase 2Unknown
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jun 2017
- Primary completion
- Nov 2017
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, open-label trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-Free Survival at 4 weeks. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03153358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153358.